To gain a deeper understanding of the role of YK01 in glioma cells in vitro, we performed MTS experiments and reported that YK01 significantly inhibited the proliferation of glioma cells with high BCL6 expression, which was almost 70-fold more potent than FX1 and almost 140-fold more potent than RI-BPI (Fig. 3A, B; Fig. S4). Here, BCL6 is linked to central nervous system cancer.